KCC2 expression is reduced in GBM cells; increased KCC2 expression in GBM cells inhibits GBM cell proliferation, i.e., KCC2 is a glioma suppressor [91] and is a prognostic marker for GBM. This evidence concerns the gene SLC12A5 and central nervous system cancer.